Zanubrutinib combinations for newly diagnosed mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of medications that include zanubrutinib (a targeted therapy) for people newly diagnosed with mantle cell lymphoma. It aims to see how well these treatments work and if they are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma and not have received any treatment for it yet.
- You must be at least 18 years old. There are two age groups: 18–64 and 65+.
- You must be able to carry out your daily activities with minimal help (ECOG score 0 to 3).
- You must have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function must meet minimum levels (your doctor can check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
This trial tests whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP or R-DHAP) helps people with untreated mantle cell lymphoma. It is for adults up to age 70 who are healthy enough for intensive treatment.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
Hear when a new Lymphoma, Mantle-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.